Member Info for pomander

Blimey Alq- quite a hatchet job, even by your high standards � did you start early today? What I fail to understand is your willingness to ridicule and mock Dr Mike at every opportunity. It would seem to me that he is rather successful participant in your Pharma world. It does smack of a personal grudge which does not serve you well. The here and now is all that counts, wilderness years as you call them are totally irrelevant if you believe the product will sell like hot cakes. Forgive me for saying that is a very old fashioned attitude. As for the license, unless you are privy to the detail, the headline numbers are only part of the equation. Whilst Andrea has indicated peak sales of �20 - �30 million she has also indicated that it could be much higher than this due to the dapoxetine effect. Clearly she is not going to big this up as would be a dumb strategic move as would a much higher milestone arrangement. Reassuring to know that exclusivity is not an issue and the Fortacin valuation as we know was a complete load of baloney.

A + B > �2 per share ? As for the $500, its not funded, even with the recent equity raise the cash burn will leave Sarepta needing to raise further funding if it becomes due. That's why I believe Sraepeta wil be taken out itself by a major pharma company if the readouts are stellar, and that is still the big if. Don't forget, most, if not all of the $500 m will be needed to meet Summ's contribution to the R & D costs, whichi are more normally borne 100% for the account of the licensor, although the limited geographical regions might be a factor. I still see Sarepta's involvement as a cheap hedge for its own shareholders.

Dr Mike is working closely with Recordati on the launch so your assertion that RP has not much of a clue as to Recordati's activities or intentions, let alone influence would seem to be incorrect. The recent profit warning of a few days ago states. Recordati has placed its initial purchase order, and manufacturing is well advanced to achieve the commercial launch in Continental Europe on time. Would seem to me, to indicate a production run beyond a few samples for Italy. Menarini ran a PE awareness campaign not just in Italy but throughout Europe. It was extensive and high profile including a TV advertising campaign during the World Cup, no doubt to capture a predominantly male audience. It also incuded a cinema campaign which was also run in the UK. Given the size of the PE addressable market, dapoxetine would seem to be both flawed and having failed to acheive any meaningful traction,and for good reasons. Fortacin is a far superior alternative in all respects. To claim there is no pressure on Recordati is complete nonesense, they are a listed company and everything they do comes with the pressure of providing returns for shareholders and growing the business. The exclusivity period also only runs to Novemeber 2023. Whilst Fortacin is not Viagra, there is a common theme, they both offer treatments to normalise sexual function. I think this will be a factor in the launch considerations. Anyway, not long to wait now.

I thought it was all getting a bit overly graphic !

He also referred to Liffe ( possible reverse t/o of the DBC) in a tweet, saying ''not started by me but will be highly finished by me. In a polished way. Follow up tweet telling investor to wait and see.

Alq- Are you suggesting that this is a strategy by design or just down to Recordati's incompetence ? It would seem pretty dumb to have commenced manufacturing in mid December 2017 the required inventory for a full E5 launch if 4/5th or 3/5 th of that inventory will sit in a warehouse for six months eating into its useful life. I can not think of any reason why Recordati would want to delay a full E5 launch. As a matter of good manners someone should also let JM know as he is putting some very bullish soundbites on his twitter feed and of course poor old JG has only just days ago ago announced in the profit warning that RP remains committed, together with Recordati S.p.A. (�Recordati�), its commercial partner, to bringing Fortacin� to market in France, Germany, Italy, Spain and Portugal in March 2018

Fristly, great news for 14 of 22 of the partcipants and lets hope the 48 week read outs provide evidence of efficacy for all particpants. Given the disconnect between the extremely positive comments on here, recent events and the share price performance I think management should now consider very carefully spinning off or splitting the C- Diff and DMD programs into stand alonecompanies. I think it creates a confused picture for investors as the drugs have no common theme and I also believe it would create some long overdue shareholder value and leave managemenet with better financing and strategic options going forwards.

262 units of FortacinTM with no marketing or promotional spend. The primary reason for the launch of FortacinTM in the UK market by Plethora was to preserve the Marketing Authorisation from lapsing in November 2016. The UK market is Recordati�s territory and we expect as Recordati rolls out the launch of FortacinTM in Europe, it will eventually take over responsibility for the UK distribution including marketing and sales from Plethora. I am more interested to know how many Plethora shifted at �20.

Surely you Google around the world, as you say or at least check out the company website before you buy the stock ?

Godchild - I understand that - my point is - do you expect the gamblers to arrive when the EU launch is announced, just as they did, in your view, when the UK launch was announced.

Goschild - I think we are somewaht at cross purposes. Cash flow did not seem to matter when volumes hit 3 billion post the UK launch.Why would you expect cash flows to become an issue post the E5 launch if we are volumes have been driven by gambers/daytraders? We have already seen some cash flow in the form of milestones ?

Too true Bignose- first time I became aware of it was Dr Mike's presentation at the Marh 2017 Investor Show. It is in the Oct 2017 presentation (Pipeline Opportunities). They are talking aout just 2 years away but I am unclear for example why RP refers to fast track under 505(b)(2) NDA as being applicable - some detail would very helpful

Interesting that you should mention Viagra - Now accepted that almost half of patients receiving Viagra don�t� respond(particularly diabetics). Generics generate $3 billion globally. There is a high probability that Regent proprietary technology similar to that used in Fortacin will lead to the development of a topical delivery formulation of this agent. The track to market or more realistically outlicensing will be relatively fast as 505(b)(2) and there will be premium pricing as therapy for a special needs population. IP protection will be at least 15 years. Currently this opportunity seems to be completely discounted in the potential value of RP.

So Godchild- do you expect the gamblers to re-emerge once the EU launch happens? If so, are we looking at circa 3 billion shares traded again perhaps or 3 billion ^5 ? As a long term RP holder and someone familiar with the HK market what's your view on the wall of money arriving ?

Bignose - indeed it will Look at the volume today - its well below the dialy average, despite the 28 m profit warning ?

Bignose - I don't follow the logic behind having to appease II's as there are none with siginificant holdings and any new shares issued would also dilute JM. If new fund managers wany to come on board they will have to buy on the market- JM is not going to reward them at his and JG's expense. A small Placing, to raise necessary funding if needed, which I doubt, to for example progress the FDA submiision would be ok with me.

I agree- its like comparing apples with oranges. DR Mike was talking of EU sales of �230 to �300 m at last years Master Investor - with royalties of 15% to 25%. This may well be a little optimistic and if accurate makes the Lisence look very much in Recordati's favour. I note Fortacin is now out of stock in the UK, clearly the price reduction did the trick. I don't know what sort of inventory levels were held but it would be interesting to know how many were sold at the lower price.

Fair comment godchild - how do you account then for 3 billion shares traded in a couple of weeks post UK launch - 650 m in just one day ? Someone or some entity must believe their is a real business ?

A 2.5% drop on just 27m traded on tha back of a profit warning (albeit a non cash item) of $28 mor circa 35% of RP's market cap. We have seen more action following Dr Mike putting his socks on the wrong way around. I am sticking with the view that this is now very tightly held with an undisclosed and large stake having been taken.

Guess you need to keep your glasses on, but forget to take off your socks !